CO-CROCS
9.12.2019 18:59:09 CET | Business Wire | Press release
Crocs, Inc. (NASDAQ: CROX), a global leader in innovative, casual footwear for women, men and children, today announced their latest product collaboration with multi-platinum recording artist Post Malone. This ground-breaking fourth installment of the Post Malone x Crocs collaboration series features the Post Malone x Crocs Duet Max Clog, an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005664/en/
The evolution of the Post Malone x Crocs partnership is evident over the four collaborations; consumers will see a transformation from previous designs that featured Post’s inspirations on the shoe, to this new silhouette incorporating his designs inside and out – including the detailing on the sole and straps, and the unique rope and lanyard clip feature. This next chapter in the Post Malone x Crocs partnership delivers a true creation from Post as he evolves his own aesthetic, and is eagerly anticipated by fans worldwide.
“This latest drop with Crocs is our best yet. I wanted to make a more tactical and chunky shoe, and they gave me all the tools to do just that,” said Post Malone. “I think they came out really neat, and I hope everyone loves them as much as I do.”
Along with the evolved and elevated design has been a differentiated reveal of the product to fans leading up to the launch. The brand first began teasing this new collaboration with a presence at Posty Fest in Arlington, TX in early November. In the weeks following, Crocs utilized a sequence of coordinated billboards to reveal the visual of the product and give fans an official first look at the design. The brand then made a surprise delivery of the coveted footwear last week and shared it with hundreds of fans and employees/customers of Chicken Express in Southlake, TX – the location of Post Malone’s first and only job prior to becoming a global music icon.
“After three collaborations – all selling out in minutes – we heard our fans demands for more and I’m pleased that this will be our biggest drop ever,” said Terence Reilly, Crocs Senior Vice President and Chief Marketing Officer. “We’re excited to give them another opportunity to own these limited-edition Post Malone x Crocs that are no doubt going to make waves around the planet.”
The limited-edition Post Malone x Crocs Duet Max Clog will be available online and at select retail locations around the world for $59.99 beginning December 10th , 2019 at 10:00 a.m. ET.
About Crocs, Inc.
Crocs, Inc. (Nasdaq: CROX) is a world leader in innovative casual footwear for women, men and children, combining comfort and style with a value that consumers know and love. Crocs’ proprietary Croslite™ material, a molded footwear technology, is included in the vast majority of Crocs’ collection and delivers extraordinary comfort with each step.
In 2019, Crocs declares that expressing yourself and being comfortable are not mutually exclusive. To learn more about Crocs or our global Come As You Are™ campaign, please visit www.crocs.com or follow @Crocs on Facebook, Instagram and Twitter.
About Post Malone:
A diamond-certified GRAMMY® Award-nominated phenomenon, Dallas, TX artist Post Malone regularly rewrites history, blurs boundaries, and incites internet-breaking conversation with every move. Emerging in 2015 with a genre-less brew that inspired a movement, he delivered the diamond-selling “Congratulations” [feat. Quavo], achieved back-to-back #1 debuts on the Billboard Top 200, received countless multiplatinum certifications around the world, and smashed one record after another with his Hot 100-topping hits. His 2019 third full-length, Hollywood’s Bleeding [Republic Records], represented an audience and critical high watermark. Not only did it arrive at platinum status and earn high praise from the likes of Pitchfork , but it also reigned at #1 on the Billboard Top 200 for four weeks and returned to the chart for a fifth week, making for the longest run atop the chart of 2019 and the first release to do so in over a year. It followed the immense success of the triple-platinum beerbongs & Bentleys , which also landed at #1 a year prior. In the wake of beerbongs & Bentleys , Post crushed a record in place for 54 years. He charted nine songs in the Top 20 of the Hot 100, notching “the most songs in the Top 20 of the Hot 100 ever .” Moreover, he also trounced the record for most simultaneous Top 40 Hot 100 hits with 14.
As of 2019, his catalog comprises the GRAMMY® Award-nominated “rockstar” [feat. 21 Savage] (8x-platinum), “Sunflower (Spider-Man: Into The Spider-Verse )” [feat. Swae Lee] (8x-platinum), “I Fall Apart” (5x-platinum), “Psycho” [feat. Ty Dolla $ign] (5x-platinum), “White Iverson” (5x-platinum), “Better Now” (4x-platinum), and more. Not to mention, he sold out numerous arena tours and launched his own mega-popular Posty Fest in its second successful year in 2019. It all started with his triple-platinum influential 2016 debut, Stoney . With records under his belt that will likely never be surpassed and a generation of artists and audiences worldwide under his spell, Post Malone simply doesn’t stop.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005664/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
